Dosage research on Tirzepatide

Preclinical research dose ranges

In published preclinical research on Tirzepatide, administered dose ranges in rodent studies have most commonly fallen in the 0.01 to 1 milligram per kilogram range delivered subcutaneously. Pharmacology studies in mice and rats characterising glucose-lowering, body-weight, and beta-cell function effects have used doses in this span. Receptor-pharmacology characterisation work (Willard and colleagues, JCI Insight 2020) described the imbalanced and biased dual-receptor agonism using in-vitro and acute in-vivo systems.

The beta-cell function and insulin sensitivity preclinical literature has used doses in a comparable range. Investigators publishing on direct effects on insulin secretion, glucagon suppression, and beta-cell mass have used 0.01 to 0.3 milligram per kilogram subcutaneously in diabetic and prediabetic rodent models across multi-week protocols.

The pharmacokinetic literature reports an approximately five-day plasma half-life in humans (supporting once-weekly dosing in clinical practice). Rodent pharmacokinetics differ and require species-specific dose-translation considerations in protocol design, with most published rodent protocols using more frequent dosing cadences than the once-weekly clinical pattern.

Clinical trial dose ranges

The published clinical-trial literature on Tirzepatide has tested specific dose levels in type 2 diabetes and obesity contexts. The SURPASS type 2 diabetes program tested 5 mg, 10 mg, and 15 mg subcutaneously once weekly. The SURMOUNT obesity program tested the same three dose levels. The SURPASS-2 head-to-head trial against semaglutide compared all three Tirzepatide doses to a single 1.0 mg dose of semaglutide in adults with type 2 diabetes.

These doses are reported here as published clinical-trial doses, not as recommendations. Tirzepatide is approved by the FDA as a human therapeutic under separate brand names that the Ronin catalog does not market; any clinical use occurs under licensed prescriber care at doses determined by the prescriber, not by reference to research-reagent vials.

Dose-response considerations from the published literature

The published Tirzepatide clinical-trial literature has reported dose-response characteristics across the SURPASS and SURMOUNT programs. HbA1c reduction and body-weight reduction scaled with dose across the 5 mg to 15 mg once-weekly subcutaneous range. SURMOUNT-1 reported approximately 20% body-weight reduction at the 15 mg dose over 72 weeks in adults with obesity without type 2 diabetes. SURPASS-4 reported cardiovascular safety against insulin glargine in patients with type 2 diabetes and increased cardiovascular risk.

Preclinical dose-response work has shown effects scaling with dose across the 0.01 to 1 milligram per kilogram rodent range on glucose tolerance, body weight, insulin secretion, and beta-cell function endpoints. The cross-species dose-translation depends on the pharmacokinetic differences between rodent and human and on the endpoint being measured.

Reconstitution math and per-vial dose calculation

A 10 mg lyophilised Tirzepatide vial reconstituted with 1 mL of bacteriostatic water yields a stock concentration of 10 mg per mL. From this stock, a research aliquot of 0.05 mL contains 500 micrograms; an aliquot of 0.05 mL contains an amount matching the SURPASS-1 lowest tested clinical dose if dosing on a per-vial basis is desired. Researchers working with rodent pharmacology dose ranges further dilute the stock to a working concentration appropriate to the model and the body weight of the animal subject. Refrigerated storage at 2 to 8 degrees Celsius, protected from light, is the standard handling practice.

Research-protocol design considerations

Protocol-design choices in the published Tirzepatide literature reflect several recurring considerations. Clinical-trial dose selection anchors at 5 mg / 10 mg / 15 mg once weekly subcutaneously for the SURPASS and SURMOUNT programs. Preclinical dose selection anchors at the 0.01 to 1 milligram per kilogram range subcutaneously in rodent models.

Route of administration in both clinical and preclinical work is overwhelmingly subcutaneous. Once-weekly dosing in clinical work is supported by the approximately five-day plasma half-life. Rodent protocols use more frequent dosing cadences (typically two-to-three times weekly) to accommodate the shorter rodent plasma half-life.

The dual GIP and GLP-1 receptor co-agonism with imbalanced and biased potency profile is a protocol-design consideration in any comparison with single-receptor GLP-1 agonists (semaglutide, liraglutide, dulaglutide). The mechanistic literature attributes a meaningful share of the differential effect over single-receptor GLP-1 agonists to the GIP-receptor co-agonism, and protocol designs comparing Tirzepatide to single-receptor GLP-1 agonists should account for this mechanistic difference.

References

1. Willard FS et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 2020. [PMID 32730231]
2. Thomas MK et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity. Journal of Clinical Endocrinology and Metabolism, 2020. [PMID 33236115]
3. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine, 2021. [PMID 34170647]
4. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet, 2021. [PMID 34672967]
5. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022. [PMID 35658024]